Jiangsu Aidea Pharmaceutical Co Ltd

Kuang-Chi Technologies' wholly owned subsidiary Kuang-Chi Advanced Technology will deliver supermaterials structural products worth a total of 907 million yuan to three customers. That evening, several listed companies disclosed major contracts and capital operations: Zhejiang Construction Investment Group's subsidiary won a public housing development project bid of about 1.5 billion Hong Kong dollars, Xianghe Industrial signed a 178 million yuan railway fastener system components sales contract, Fulongma signed a 200 million yuan sanitation autonomous driving technology development contract with Huawei Cloud Computing, and Aidea Pharmaceutical plans a private placement to raise no more than 945 million yuan for the global clinical development of a novel HIV integrase inhibitor and other projects. Hengrui Pharmaceuticals repurchased 335,000 A-shares for the first time that day, paying 14.5036 million yuan. Longshen Rongfa's controlling subsidiary's marketing application for brexpiprazole oral dissolving film was not approved. In that day's Dragon-Tiger List, MetaX, one of the leading domestic GPU companies, saw the largest net institutional selling of 2.142 billion yuan, while its share price rose more than 14 percent; Ruifeng Advanced Materials saw the largest net institutional buying of 212 million yuan.

Aidea Pharmaceutical released its 2026 interim report, with total operating revenue of 366 million yuan and net profit attributable to the parent company of 22.93 million yuan. The company's net cash inflow from operating activities was 25.06 million yuan, its asset-liability ratio was 50.67%, gross margin was 65.49%, return on equity was 2.51%, and diluted earnings per share was 0.05 yuan. The number of shareholders was 12,200, and the top ten shareholders held 58.66% of the total share capital.